SOLIRIS (eculizumab): The first treatment specifically approved for PNH

For US Healthcare Professionals

SOLIRIS and Patient Quality of Life

SOLIRIS has a clinically significant impact on quality of life

Clinical impact of SOLIRIS on fatigue, global health, and patient functioning1,2

SOLIRIS and Patient Quality of Life

  • Standard effect size (SES) was used to determine the magnitude of clinical benefit2
     
  • A large impact on fatigue was demonstrated in 2 independent instruments1-3
     
  • SOLIRIS® (eculizumab) has a statistically significant impact on measures including fatigue and global health status, in addition to role, social, cognitive, physical, and emotional functioning1-3
     

SOLIRIS has a clinically significant impact on disease-related symptoms

Clinical impact of SOLIRIS on disease-related symptoms1,2

SOLIRIS and Patient Quality of Life

  • SOLIRIS has a moderate and statistically significant impact on dyspnea and pain1-3
     
  • SOLIRIS has a statistically significant impact on other symptoms including insomnia, and appetite loss1-3

Next: Fewer Thrombotic Events

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS MENINGOCOCCAL INFECTION

SOLIRIS® increases the risk of meningococcal infections.

Vaccinate patients with a meningococcal vaccine at least 2 weeks prior to receiving the first dose of SOLIRIS; revaccinate according to current medication guidelines for vaccine use.

Monitor patients for early signs of meningococcal infections, evaluate immediately if infection is suspected, and treat with antibiotics if necessary.

The effect of withdrawal of anticoagulant therapy during SOLIRIS treatment has not been established. Therefore, treatment with SOLIRIS should not alter anticoagulant management.

SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING INCLUDING WARNINGS, PRECAUTIONS, AND ADVERSE REACTIONS.

The most frequent adverse events observed in clinical studies were headache, nasopharyngitis, back pain, nausea, fatigue, and cough.

Please see important safety information (including boxed warning) as well as the complete prescribing information.

References:
1. SOLIRIS® prescribing information. Alexion Pharmaceuticals, Inc. 2007.
2. Data on File. Alexion Pharmaceuticals, Inc.
3. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.